Buradasınız

Anasayfa » Content

Sistemik Lupus Eritematozuslu Bir Olguda Aort Yetmezliği Nedeniyle Aort Kapak Replasmanı

Aortic valve replacement in a systemic lupus erythematosus patient with aortic insufficiency

Journal Name:

  • Cerrahpaşa Tıp Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Systemic Lupus Erythematosus is associated with substantial morbidity and mortality if the patient has valvular heart disease. Aortic insufficiency was detected in a thirty-one year old man with Systemic Lupus Erythematosus nephritis and positive ANA on the 11th year of his corticosteroid treatment. The patient underwent aortic valve replacement and he was discharged without complications.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-sistemik-lupus-eritematozuslu-bir-olguda-aort-yetmezligi-nedeniyle-aort-kapak-replasmani.pdf
  • 2
73-75
  • Turkish

REFERENCES

References: 

1. Dajee H, Hurley EJ, Szarnicki RJ. Cardiac valve
replacement in systemic lupus erythematosus. A
review. J Thorac Cardiovasc Surg 1983; 85: 718-726.
2. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart
valve involvement (Libman–Sacks endocarditis) in the
antiphospholipid syndrome. Circulation 1996; 93:
1579-1587.
3. Kumar S, Sinha B, Ravikumar E. Emergency aortic
valve replacement in systemic lupus erythematosus.
Heart Lung Circ 2006; 15: 397-399.
4. Knockaert DC. Cardiac involvement in systemic
inflammatory diseases. Eur Heart J 2007; 28: 1797-
1804.
5. Nobrega TP, Klodas E, Breen JF, et al. Giant coronary
artery aneurysms and myocardial infarction in a
patient with systemic lupus erythematosus. Cathet
Cadiovasc Diagn 1996; 39: 75-79.
6. Sharma AK, Farb A, Maniar P, et al. Spontaneous coronary
artery dissection in a patient with systemic lupus
erythematosis. Hawaii Med J 2003; 62: 248-253.
7. Schattner A, Liang MH. The cardiovascular burden of
lupus: a complex challenge. Arch Intern Med 2003;
163: 1507-1510.
8. Asanuma Y, Oeser A, Shintani AK, et al. Premature
coronary-artery atherosclerosis in systemic lupus erythematosus.
N Engl J Med 2003; 349: 2407-2415.
9. Boumpas DT, Austin HA III, Fessler BJ, et al. Systemic
lupus erythematosus: emerging concepts. Ann Intern
Med 1995; 122: 940-950.
10. Hahn BH. Systemic lupus erythematosus and accelerated
atherosclerosis. N Engl J Med 2004; 349: 2379-
2380.
11. Roman MJ, Shanker BA, Davis A, et al. Prevalence and
correlates of accelerated atherosclerosis in systemic
lupus erythematosus. N Engl J Med 2003; 349:
2399–2406.
12. Roldan CA, Shively BK, Crawford MH. An
Echocardiographic Study of Valvular Heart Disease
Associated with Systemic Lupus Erythematosus. N Engl
J Med 1996; 335: 1424-1430.
13. Khamashta MA, Cervera R, Asherson RA, et al.
Association of antibodies against phospholipids with
heart valve disease in systemic lupus erythematosus.
Lancet 1990; 335: 1541-1544.
14. Jonsson CA, Svensson L. Beneficial effect of the inosine
monophosphate Dehydrogenase inhibitor
mycophenolate mofetil on survival and severity of
glomerulonephritis in systemic lupus erythematosus
(SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol 1999;
116: 534-541.

Thank you for copying data from http://www.arastirmax.com